CAMK2G and cardiomyopathy: Therefore, it would be interesting in future studies to address whether compounds like C32 and C4 can be used in therapeutic/preventive applications for diseases associated with CaMKII over-activation in CRABP1-positive cells/tissues, such as progressive motor deterioration and cardiomyopathy as revealed in the CKO mouse model.